The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD

Monoamine oxidase (MAO) has been implicated in neuroinflammation, and therapies targeting MAO are of interest for neurodegenerative diseases. The small-molecule drug tranylcypromine, an inhibitor of MAO, is currently used as an antidepressant and in the treatment of cancer. However, whether tranylcypromine can regulate LPS- and/or Aβ-induced neuroinflammation in the brain has not been well-studied. In the present study, we found that tranylcypromine selectively altered LPS-induced proinflammatory cytokine levels in BV2 microglial cells but not primary astrocytes. In addition, tranylcypromine modulated LPS-mediated TLR4/ERK/STAT3 signaling to alter neuroinflammatory responses in BV2 microglial cells. Importantly, tranylcypromine significantly reduced microglial activation as well as proinflammatory cytokine levels in LPS-injected wild-type mice. Moreover, injection of tranylcypromine in 5xFAD mice (a mouse model of AD) significantly decreased microglial activation but had smaller effects on astrocyte activation. Taken together, our results suggest that tranylcypromine can suppress LPS- and Aβ-induced neuroinflammatory responses in vitro and in vivo.

[1]  Wei Jiang,et al.  Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. , 2020, Journal of affective disorders.

[2]  H. Hoe,et al.  Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling , 2019, Journal of Neuroinflammation.

[3]  Xingkai Zhang,et al.  The effects of tranylcypromine on osteoclastogenesis in vitro and in vivo , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  C. Popoiu,et al.  MONOAMINE OXIDASE IS A SOURCE OF OXIDATIVE STRESS IN OBESE PATIENTS WITH CHRONIC INFLAMMATION. , 2019, Canadian journal of physiology and pharmacology.

[5]  C. Popoiu,et al.  Monoamine Oxidase-Related Vascular Oxidative Stress in Diseases Associated with Inflammatory Burden , 2019, Oxidative medicine and cellular longevity.

[6]  Ashwini M. Londhe,et al.  Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease , 2019, Science Advances.

[7]  J. Schütte,et al.  LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML , 2019, Leukemia.

[8]  T. Deierborg,et al.  Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response , 2018, Front. Cell. Neurosci..

[9]  H. Choi,et al.  The small molecule CA140 inhibits the neuroinflammatory response in wild-type mice and a mouse model of AD , 2018, Journal of Neuroinflammation.

[10]  Jeongyeon Kim,et al.  Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice , 2018, Journal of Neuroinflammation.

[11]  D. Muntean,et al.  Monoamine oxidase inhibition improves vascular function and reduces oxidative stress in rats with lipopolysaccharide-induced inflammation. , 2018, General physiology and biophysics.

[12]  K. Biswas,et al.  Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13–stimulated monocytes and A549 lung carcinoma cells , 2018, The Journal of Biological Chemistry.

[13]  Yu-bo Zhou,et al.  Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. , 2017, European journal of medicinal chemistry.

[14]  D. Westaway,et al.  Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation , 2017, Journal of Neuroinflammation.

[15]  P. Schlattmann,et al.  Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression , 2017, European Neuropsychopharmacology.

[16]  L. Schneider,et al.  Defeating Alzheimer's disease and other dementias: a priority for European science and society , 2016, The Lancet Neurology.

[17]  F. Drago,et al.  Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. , 2015, European journal of pharmacology.

[18]  W. V. van Gool,et al.  Systemic inflammation and microglial activation: systematic review of animal experiments , 2015, Journal of Neuroinflammation.

[19]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[20]  R. Cacabelos,et al.  Epigenetic drug discovery for Alzheimer’s disease , 2014, Expert opinion on drug discovery.

[21]  C. Cunningham,et al.  Correction: A Systematic Analysis of the Peripheral and CNS Effects of Systemic LPS, IL-1β, TNF-α and IL-6 Challenges in C57BL/6 Mice , 2013, PLoS ONE.

[22]  C. Cunningham,et al.  A Systematic Analysis of the Peripheral and CNS Effects of Systemic LPS, IL-1Β, TNF-α and IL-6 Challenges in C57BL/6 Mice , 2013, PloS one.

[23]  H. Nakayama,et al.  Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B. , 2013, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[24]  Yung-Hyun Choi,et al.  Caffeine suppresses lipopolysaccharide-stimulated BV2 microglial cells by suppressing Akt-mediated NF-κB activation and ERK phosphorylation. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  Xingshu Li,et al.  Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. , 2012, Journal of medicinal chemistry.

[26]  Phenelzine (Monoamine Oxidase Inhibitor) Increases Production of Nitric Oxide and Proinflammatory Cytokines via the NF-κB Pathway in Lipopolysaccharide-Activated Microglia Cells , 2012, Neurochemical Research.

[27]  M. Youdim,et al.  From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. , 2012, Mini reviews in medicinal chemistry.

[28]  S. Rose-John,et al.  IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3 , 2011, The Journal of Immunology.

[29]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[30]  E. Obuchowicz,et al.  Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  M. Youdim,et al.  Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. , 2010, ACS chemical biology.

[32]  J. Belluzzi,et al.  Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats , 2010, Psychopharmacology.

[33]  J. Changeux,et al.  Regional changes in the cholinergic system in mice lacking monoamine oxidase A , 2009, Brain Research Bulletin.

[34]  B. Gorzalka,et al.  Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents , 2008, Journal of Neural Transmission.

[35]  David M. Gooden,et al.  Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. , 2008, Bioorganic & medicinal chemistry letters.

[36]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[37]  D. Bylund,et al.  Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression , 2008, Psychopharmacology.

[38]  J. Belluzzi,et al.  Monoamine Oxidase Inhibitors Allow Locomotor and Rewarding Responses to Nicotine , 2006, Neuropsychopharmacology.

[39]  M. Youdim,et al.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.

[40]  Y. Akao,et al.  Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. , 2006, Journal of neural transmission. Supplementum.

[41]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[42]  R. El Bekay,et al.  A new role for monoamine oxidases in the modulation of macrophage‐inducible nitric oxide synthase gene expression , 2004, Journal of leukocyte biology.

[43]  Rolf Rossaint,et al.  Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3 1 , 2003, The Journal of Immunology.

[44]  A. Parini,et al.  Monoamine oxidase B induces ERK-dependent cell mitogenesis by hydrogen peroxide generation. , 2000, Biochemical and biophysical research communications.

[45]  S. L. Yates,et al.  Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia , 2000, Journal of neurochemistry.

[46]  E. Nowakowska,et al.  [Inhibitory monoamine oxidases of the new generation]. , 1997, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[47]  J. Cummings.  Lewy Body Diseases with Dementia - Pathophysiology and Treatment , 1995, Brain and Cognition.

[48]  D. McManus,et al.  Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. , 1994, Journal of neural transmission. Supplementum.

[49]  M. Youdim,et al.  Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. , 1994, Life sciences.

[50]  S. Belliard,et al.  Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. , 1994, Journal of neural transmission. Supplementum.

[51]  K. Kato,et al.  Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein , 1992, The Journal of experimental medicine.

[52]  S. Ross,et al.  Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. , 1986, Biochemical pharmacology.

[53]  J. Mann,et al.  Studies of selective and reversible monoamine oxidase inhibitors. , 1984, The Journal of clinical psychiatry.